

# Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United States

## HEARING

Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United States

Subcommittee on Health  
Wednesday, May 2, 2007, 10:00 a.m.  
2123 Rayburn House Office Building

Hearing Webcast

(Any use of this recording is subject to Rule XI, 4 of the House of Representatives. See text of Rule XI, 4 as posted by the House Committee on Rules.)

Connect to the Archived Video Webcast of this Hearing (100 kbps) or Download

Windows Media Player is required for Committee Webcasts.

Witness List & Prepared Testimony (pdf files)

### Panel I

Janet Woodcock, M.D.  
Deputy Commissioner and Chief Medical Officer  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

### Panel II

Geoffrey Allan, Ph.D.  
President, CEO, Chairman of the Board  
Insmmed Incorporated  
8720 Stony Point Parkway  
Suite 200  
Richmond, VA 23235

David Schenkein, M.D.  
Vice President

Clinical Hematology/Oncology Genentech, Inc.  
1 DNA Way  
Mailstop 444B  
South San Francisco, CA 94080

Bruce Downey, J.D.  
Chairman of the Board  
Generic Pharmaceutical Association  
Chairman and CEO  
Barr Pharmaceuticals, Inc.  
400 Chestnut Ridge Road  
Woodcliff Lake, NJ 07677  
William Schwieterman, M.D.  
Tekgenics, Inc.  
3901 Point Road  
Mobile, AL 36619

Ms. Ruth Hoffman  
Executive Director  
The Candlelighters  
Childhood Cancer Foundation  
3910 Warner Street  
Kensington, MD 20895-0498  
Ed Weisbart, M.D.  
Chief Medical Officer  
Medical Affairs  
Express Scripts, Inc.  
13900 Riverport Drive  
Maryland Heights, MO 63042

Richard F. Kingham, J.D.  
Partner  
Covington & Burling  
1201 Pennsylvania Avenue, NW  
Washington, DC 20004

Hearing Transcript

Not available at this time. The printed hearing should be available within 90-120 days of the conclusion of the hearing. When available, the text of the printed hearing may be viewed at the U.S. Government Printing Office Web site.